Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 76, Issue 2, 2007, Pages 177-186

  Vasylyeva, Tetyana L ^a   Ferry Jr , Robert J ^b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Texas Army National Guard   (United States)

Author keywords

Diabetic nephropathy; IGF; IGF receptor; IGFBPs

Indexed keywords

AMINOGUANIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; PROTEINASE; PTR 3173; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING AFFINITY; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM CELL; GLOMERULUS; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTROPHY; KIDNEY CELL; KIDNEY DISEASE; KIDNEY PARENCHYMA; MESANGIUM CELL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PODOCYTE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; SOMATOMEDINS;

EID: 33947264716     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.09.012     Document Type: Review

References (61)

1. Chiarelli F., Trotta D., Verrotti A., and Mohn A. Kidney involvement and disease in patients with diabetes. Panminerva Med. 45 (2003) 23-41
2. Campbell F. Microalbuminuria and nephropathy in insulin-dependent diabetes mellitus. Arch. Dis. Child 73 (1995) 4-7
3. Quattrin T., Waz W.R., Duffy L., Sheldon M.W., Campos S.P., Albini C.H., et al. Microalbuminuria in an adolescent cohort with insulin-dependent diabetes mellitus. Clin. Pediatr. 34 (1995) 12-17
4. Mauer S., Steffes M., and Brown D. The kidney in diabetes. Am. J. Med. 70 (1981) 603-612
5. Mauer S., Steffes M., Ellis E., Sutherland D., Brown D.M., and Goetz F.C. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 74 (1984) 1143-1155
6. Osterby R. A quantitative electron microscopic study of mesangial regions in glomeruli from patients with short-term juvenile diabetes mellitus. Lab. Invest. 29 (1973) 99-110
7. Steffes M.W., Osterby R., Chavers B., and Mayer S.M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38 (1989) 1077-1081
8. Karl M., Potier M., Schulman I., Rivera A., Werner H., Fornoni A., et al. Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells. Endocrinology 146 (2005) 889-900
9. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43 (2000) 1205-1223
10. Flyvbjerg A., Frystyk J., Osterby R., and Orskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am. J. Physiol. 262 (1992) E956-E962
11. Flyvbjerg A., Khatir D., Jensen L., Dagnæs-Hansen F., Gronbaek H., and Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr. Pharm. Des. 10 (2004) 3385-3394
12. Ferry Jr. R.J., and Cohen P. The insulin-like growth factor axis in pediatrics. Clin. Pediatr. Endocrinol. 8 (1999) 1-10
13. Firth S., and Baxter R. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
14. Raz I., Wexler I., Weiss O., Flyvbjerg A., Segev Y., Rauchwerger A., et al. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat). Nephrol. Dial. Transplant. 18 (2003) 1293-1298
15. Gambaro G., and Baggio B. Growth factors and the kidney in diabetes mellitus. Crit. Rev. Clin. Lab. Sci. 35 (1998) 117-151
16. Garay-Sevilla M., Nava L., Malacara J., Nava L.E., Wrobel-Zasada K., Castro-Rivas A., et al. Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diab. Metab. Res. Rev. 16 (2000) 106-113
17. Fornoni A., Li H., Foschi A., and Stiker L.J. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am. J. Pathol. 158 (2001) 275-280
18. Abrass C., Raugi G., Gabourel L., and Lovet D.H. Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology 123 (1988) 2432-2439
19. Sanaka T. Nutritional effect of dialysis therapy. Artif. Organs 27 (2003) 224-226
20. Abrass C., Berfield A., and Andress D. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am. J. Physiol. 273 (1997) F899-F906
21. Berfield A., Andress D., and Abrass C. IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function. Kidney Int. 62 (2002) 1229-1237
22. Phillips S., DeRubertis F., and Craven P. Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes 48 (1999) 2083-2089
23. Trachtman H., Koss I., Bogart M., Abramowitz J., Futterweit S., Franki N., et al. High glucose enhances growth factor-stimulated nitric oxide production by cultured rat mesangial cells. Res. Commun. Mol. Pathol. Pharmacol. 100 (1998) 213-225
24. Vasylyeva T.L., Chen X., and Ferry Jr. R.J. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesengial cell apoptosis. Growth Horm. IGF Res. 15 3 (2005) 207-214
25. Berfield A., Spicer D., and Abrass C. Insulin-like growth factor I (IGF-I) induces unique effects in the cytoskeleton of cultured rat glomerular mesangial cells. J. Histochem. Cytochem. 45 (1997) 583-593
26. Horney M., Shirley D., Kurtz D., and Rosenzweig S.A. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am. J. Physiol. 274 (1998) F1045-F1053
27. White K., Bilous R., Marshall S., El Nahas M., Remuzzi G., Piras G., et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51 (2002) 3083-3089
28. Sukegawa I., Hizuka N., Takano K., Asakawa K., and Shizume K. Characterization of insulin-like growth factor I receptors on Madin-Darby canine kidney (MDCK) cell line. Endocrinol. Jpn. 34 (1987) 339-346
29. Li W., Fawcett J., Widmer H.R., Fielder P.J., Rabkin R., and Keller G.-A. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 138 (1997) 1763-1766
30. Senthil D., Choudhury G., Abboud H., Sonenberg N., and Kasinath B.S. Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 283 (2002) F1226-F1236
31. Shalamanova L., Kubler B., Scharf J.G., and Braulke T. MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E1221-E1229
32. Tsilibary E. Microvascular basement membranes in diabetes mellitus. J. Pathol. 200 (2003) 537-546
33. Makino H., Sugimoto H., and Shikata K. Diabetic nephropathy-recent advances in its mechanism and treatment. Nippon Rinsho 57 (1999) 590-600
34. Flyvbjerg A. Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease. Growth Horm. IGF Res. 11 (2001) S115-S119
35. Doi T., Striker L.J., Gibson C.C., Agodoa L.Y., Brinster R.L., and Striker G.E. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am. J. Pathol. 137 (1990) 541-552
36. Cingel-Ristic V., Schrijvers B.F., van Vliet A.K., Rash R., Han V., Drop S.L., et al. Kidney growth in normal and diabetic mice is not affected by human insulin-like growth factor binding protein-1 administration. Exp. Biol. Med. 230 (2005) 135-143
37. Doublier S., Seurin D., Fouqueray B., Verpont C., Callard P., Striker L.J., et al. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int. 57 (2000) 2299-2307
38. Bortz J., Rotwein P., DeVol D., Bechtel P.J., Hansen V.A., and Hammerman M.P. Focal expression of insulin-like growth factor I in rat kidney collecting duct. J. Cell Biol. 107 (1988) 811-819
39. Werner H., Shen-Orr Z., Stannard B., Burguera B., Roberts Jr. C.T., and LeRoith D. Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney. Diabetes 39 (1990) 1490-1497
40. Landau D., Israel E., Rivkis I., Kachko L., Schrijvers B.F., Flyvbjerg A., et al. The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol. Dial. Transplant. 18 (2003) 694-702
41. Wang S., Lapage J., and Hirschberg R. Glomerular ultrafiltration of IGF-I may contribute to increased renal sodium retention in diabetic nephropathy. J. Lab. Clin. Med. 134 (1999) 154-160
42. Phillip M., Werner H., Palese T., Kowarski A.A., Stannard B., Bach L.A., et al. Differential accumulation of insulin-like growth factor-I in kidneys of pre- and postpubertal streptozotocin-diabetic rats. J. Mol. Endocrinol. 12 (1994) 215-224
43. Miyatake N., Shikata K., Wada J., Sugimoto H., Takahashi S.-I., and Makino H. Differential distribution of insulin-like growth factor-1 and insulin-like growth factor binding proteins in experimental diabetic rat kidney. Nephron 81 (1999) 317-323
44. Park I., Kiyomoto H., Alvarez F., Xu Y.C., Abboud H.E., and Abboud S.L. Preferential expression of insulin-like growth factor binding proteins-1, -3, and -5 during early diabetic renal hypertrophy in rats. Am. J. Kidney Dis. 32 (1998) 1000-1010
45. Spagnoli A., Chiarelli F., Vorwerk P., Boscherini B., and Rosenfeld R.G. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment. Clin Endocrinol 51 (1999) 587-596
46. Verrotti A., Cieri F., Petitti M.T., Morgese G., and Chiarelli F. Growth hormone and IGF-I in diabetic children with and without microalbuminuria. Diab. Nutr. Metab. 12 (1999) 271-276
47. Shinada M., Akdeniz A., Panagiotopoulos S., Jerums G., and Bach L.A. Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J. Clin. Endocrinol. Metab. 85 (2000) 1163-1169
48. Jehle P.M., Jehle D.R., Mohan S., and Bochm B.O. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J. Endocrinol. 159 (1998) 297-306
49. Gambaro G., and Baggio B. Growth factors and the kidney in diabetes mellitus. Crit. Rev. Clin. Lab. Sci. 35 (1998) 117-151
50. Bambola O., and Kaskel F. Growth hormone therapy in chronic kidney disease. Growth Genet. Horm. 12 (2005) 7-14
51. Landau D., Segev Y., and Afargan M. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int. 60 (2001) 505-512
52. Segev Y., Landau D., Rasch R., Flyvbjerg A., and Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J. Am. Soc. Nephrol. 10 (1999) 2374-2381
53. Bach L.A. IGF-I and IGF binding proteins in diabetes-related kidney growth. Growth Regul. 2 (1992) 30-39
54. Orskov H. Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes?. Metabolism 45 (1996) 91-95
55. Chen N.Y., Chen W.Y., Bellush L., Yang C.W., Striker L.J., Striker G.E., et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 136 (1995) 660-667
56. Bach L., Dean R., Youssef S., and Cooper M.E. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol. Dial. Transplant. 15 (2000) 347-354
57. P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, Recombinant Human Insulin-Like Growth Factor-I (rhIGF-1) treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 Diabetes Mellitus (DM), Endocrinology, 2006 (epub ahead of print).
58. Segev Y., Eshet R., Rivkis I., Hayat C., Kachko L., Phillip M., et al. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Nephrol. Dial. Transplant. 19 (2004) 3021-3028
59. Alric Pecher C., Cellier E., Schanstra J.P., Poirier B., Chevalier J., et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int. 62 (2002) 412-421
60. Chen X., and Ferry Jr. R.J. Novel actions of IGFBP-3 on intracellular signaling pathways in insulin-secreting cells. Growth Horm. IGF Res. 16 (2006) 41-48 (Erratum in Growth Horm. IGF Res. 16 (2006) 276)
61. Franklin S.L., Ferry Jr. R.J., and Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J. Clin. Endocrinol. Metab. 88 (2003) 900-907